Thalassemia News and Research

Latest Thalassemia News and Research

Study: Ciclopirox drug completely eradicates infectious HIV from cell cultures

The topical anti-fungal drug Ciclopirox causes HIV-infected cells to commit suicide by jamming up the cells' powerhouse, the mitochondria—according to a study by researchers at Rutgers New Jersey Medical School. And unlike current anti-HIV drugs, Ciclopirox completely eradicates infectious HIV from cell cultures, with no rebound of virus when the drug is stopped.

24 Sep 2013

Global Industry Analysis Report on Companion Diagnostics Market

New Market Research Report Added in MarketResearchReports.Biz Reports Database Companion Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

12 Sep 2013

Sangamo BioSciences signs definitive agreement to buy Ceregene

Sangamo BioSciences, Inc. announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus gene therapies.

26 Aug 2013

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B.

17 Aug 2013

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase I trial of ALN-TTRsc, a subcutaneously administered RNAi therapeutic targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

12 Jul 2013

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from its RNAi therapeutic program for the treatment of hemophilia and rare bleeding disorders.

2 Jul 2013

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with ALN-CC5, an RNAi therapeutic targeting complement component C5.

21 Jun 2013

Cerus enrolls patient in two European clinical trials for INTERCEPT System for RBCs

Cerus Corporation announced today that it has initiated patient enrollment in two European Phase III clinical trials for the INTERCEPT System for red blood cells.

11 Jun 2013

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.

18 May 2013

New partnership to introduce advanced genetic testing technologies to Turkey

BGI Health and ACIBADEM Healthcare Group Genetic Diagnostic Center in cooperation with Genoks Company Molecular Biology, signed a Memorandum of Understanding for jointly introducing the advanced genetic testing technologies to Turkey and improving Turkish reproductive healthcare.

17 Apr 2013

Two studies shed light on molecular biology of three blood disorders

Two studies led by investigators at Weill Cornell Medical College shed light on the molecular biology of three blood disorders, leading to novel strategies to treat these diseases.

26 Mar 2013

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.

7 Mar 2013

Gamida Cell announces results from NiCord Phase I/II study on hematological malignancies

Gamida Cell announced today the successful results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's proprietary NAM technology.

15 Feb 2013

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Sangamo BioSciences, Inc. today reported fourth quarter and full year 2012 financial results and accomplishments.

7 Feb 2013

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

The U.S. Food and Drug Administration recently announced the authorization of FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

31 Jan 2013

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its investigational protein therapeutic, ACE-536, to treat anemia in patients with myelodysplastic syndromes (MDS).

30 Jan 2013

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

23 Jan 2013

Penn Medicine to establish new center for treatment and research of blood diseases

Penn Medicine will establish the Philadelphia region's first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses.

18 Jan 2013

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.

11 Dec 2012

Sickle cell disease trial completes phase 3 patient enrollment

Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine company, today announced the completion of patient enrollment for its phase 3 clinical trial to study L-glutamine as a treatment for sickle cell disease.

5 Dec 2012

Thalassemia News and Research

Latest Thalassemia News and Research

Study: Ciclopirox drug completely eradicates infectious HIV from cell cultures

Global Industry Analysis Report on Companion Diagnostics Market

Sangamo BioSciences signs definitive agreement to buy Ceregene

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam presents new pre-clinical data of ALN-CC5 for treatment of complement-mediated diseases

Cerus enrolls patient in two European clinical trials for INTERCEPT System for RBCs

Alnylam reports pre-clinical data from ALN-AS1 program for treatment of AIP

New partnership to introduce advanced genetic testing technologies to Turkey

Two studies shed light on molecular biology of three blood disorders

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Gamida Cell announces results from NiCord Phase I/II study on hematological malignancies

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Novartis receives FDA approval for Exjade to treat chronic iron overload in NTDT patients

Penn Medicine to establish new center for treatment and research of blood diseases

Acetylon announces results from selective HDAC 1/2 inhibitor preclinical study on SCD and bT

Sickle cell disease trial completes phase 3 patient enrollment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Thalassemia News and Research

Latest Thalassemia News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in